Groups

Groups
E-mail Print PDF

2018

Daina A, Giuliano C, Pietra C, Wang J, Chi Y, Zou Z, Li F, Yan Z, Zhou Y, Guainazzi A, Garcia Rubio S, Zoete V.
Rational Design, Synthesis, and Pharmacological Characterization of Novel Ghrelin Receptor Inverse Agonists as Potential Treatment against Obesity-Related Metabolic Diseases.
J Med Chem. 2018 Oct 15. doi: 10.1021/acs.jmedchem.8b00794. [Epub ahead of print]


Daina A, Blatter MC, Gerritsen VB, Zoete V.
Educational Tools to Introduce Computer-Aided Drug Design to Students and to the Public at Large.
Chimia (Aarau). 2018 Feb 1;72(1):55-61. doi: 10.2533/chimia.2018.55.


Bobisse S, Genolet R, Roberti A, Tanyi JL, Racle J, Stevenson BJ, Iseli C, Michel A, Le Bitoux MA, Guillaume P, Schmidt J, Bianchi V, Dangaj D, Fenwick C, Derré L, Xenarios I, Michielin O, Romero P, Monos DS, Zoete V, Gfeller D, Kandalaft LE, Coukos G, Harari A.
Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer.
Nat Commun. 2018 Mar 15;9(1):1092. doi: 10.1038/s41467-018-03301-0.


Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R, Baumgartner P, Stevenson BJ, Iseli C, Dangaj D, Czerniecki B, Semilietof A, Racle J, Michel A, Xenarios I, Chiang C, Monos DS, Torigian DA, Nisenbaum HL, Michielin O, June CH, Levine BL, Powell DJ Jr, Gfeller D, Mick R, Dafni U, Zoete V, Harari A, Coukos G, Kandalaft LE.>br> Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.
Sci Transl Med. 2018 Apr 11;10(436). pii: eaao5931. doi: 10.1126/scitranslmed.aao5931.


Battistello E, Katanayeva N, Dheilly E, Tavernari D, Donaldson MC, Bonsignore L, Thome M, Christie AL, Murakami MA, Michielin O, Ciriello G, Zoete V, Oricchio E.
Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma.
Blood. 2018 May 24;131(21):2345-2356. doi: 10.1182/blood-2017-10-809210. Epub 2018 Mar 22.


Bovay A, Zoete V, Dolton G, Bulek AM, Cole DK, Rizkallah PJ, Fuller A, Beck K, Michielin O, Speiser DE, Sewell AK, Fuertes Marraco SA.
T cell receptor alpha variable 12-2 bias in the immunodominant response to Yellow fever virus.
Eur J Immunol. 2018 Feb;48(2):258-272. doi: 10.1002/eji.201747082. Epub 2017 Dec 11.


Kapuria V, Röhrig UF, Waridel P, Lammers F, Borodkin VS, van Aalten DMF, Zoete V, Herr W.
The conserved threonine-rich region of the HCF-1PRO repeat activates promiscuous OGT:UDP-GlcNAc glycosylation and proteolysis activities.
J Biol Chem. 2018 Nov 16;293(46):17754-17768. doi: 10.1074/jbc.RA118.004185. Epub 2018 Sep 17.


Ansar M, Paracha SA, Serretti A, Sarwar MT, Khan J, Ranza E, Falconnet E, Iwaszkiewicz J, Shah SF, Qaisar AA, Santoni FA, Zoete V, Megarbane A, Ahmed J, Colombo R, Makrythanasis P, Antonarakis SE.
Biallelic variants in FBXL3 cause intellectual disability, delayed motor development and short stature.
Hum Mol Genet. 2018 Nov 26. doi: 10.1093/hmg/ddy406. [Epub ahead of print]


Front S, Almeida S, Zoete V, Charollais-Thoenig J, Gallienne E, Marmy C, Pilloud V, Marti R, Wood T, Martin OR, Demotz S.
4-epi-Isofagomine derivatives as pharmacological chaperones for the treatment of lysosomal diseases linked to β-galactosidase mutations: Improved synthesis and biological investigations.
Bioorg Med Chem. 2018 Nov 1;26(20):5462-5469. doi: 10.1016/j.bmc.2018.09.023. Epub 2018 Sep 21.


Makrythanasis P, Maroofian R, Stray-Pedersen A, Musaev D, Zaki MS, Mahmoud IG, Selim L, Elbadawy A, Jhangiani SN, Coban Akdemir ZH, Gambin T, Sorte HS, Heiberg A, McEvoy-Venneri J, James KN, Stanley V, Belandres D, Guipponi M, Santoni FA, Ahangari N, Tara F, Doosti M, Iwaszkiewicz J, Zoete V, Backe PH, Hamamy H, Gleeson JG, Lupski JR, Karimiani EG, Antonarakis SE.
Biallelic variants in KIF14 cause intellectual disability with microcephaly.
Eur J Hum Genet. 2018 Mar;26(3):330-339. doi: 10.1038/s41431-017-0088-9. Epub 2018 Jan 17.


Ghosn J, Vicino A, Michielin O, Coukos G, Kuntzer T, Obeid M.
A severe case of neuro-Sjögren's syndrome induced by pembrolizumab.
J Immunother Cancer. 2018 Oct 22;6(1):110. doi: 10.1186/s40425-018-0429-4.


Kudchadkar RR, Michielin O, van Akkooi ACJ.
Practice-Changing Developments in Stage III Melanoma: Surgery, Adjuvant Targeted Therapy, and Immunotherapy.
Am Soc Clin Oncol Educ Book. 2018 May 23;(38):759-762. doi: 10.1200/EDBK_200241. Review.


Bordry N, Broggi MAS, de Jonge K, Schaeuble K, Gannon PO, Foukas PG, Danenberg E, Romano E, Baumgaertner P, Fankhauser M, Wald N, Cagnon L, Abed-Maillard S, Maby-El Hajjami H, Murray T, Ioannidou K, Letovanec I, Yan P, Michielin O, Matter M, Swartz MA, Speiser DE.
Lymphatic vessel density is associated with CD8+ T cell infiltration and immunosuppressive factors in human melanoma.
Oncoimmunology. 2018 May 31;7(8):e1462878. doi: 10.1080/2162402X.2018.1462878. eCollection 2018.


Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman ME, Gansert J, Hodi FS, Long GV.
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
Cell. 2018 Aug 9;174(4):1031-1032. doi: 10.1016/j.cell.2018.07.035.


Dummer R, Michielin O, Nägeli MC, M Goldinger S, Campigotto F, Kriemler-Krahn U, Schmid H, Pedroncelli A, Micaletto S, Schadendorf D.
Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanoma.
ESMO Open. 2018 Jul 23;3(5):e000388. doi: 10.1136/esmoopen-2018-000388. eCollection 2018.


Raisaro JL, Troncoso-Pastoriza J, Misbach M, Sa Sousa J, Pradervand S, Missiaglia E, Michielin O, Ford B, Hubaux JP.
MedCo: Enabling Secure and Privacy-Preserving Exploration of Distributed Clinical and Genomic Data.
IEEE/ACM Trans Comput Biol Bioinform. 2018 Jul 13. doi: 10.1109/TCBB.2018.2854776. [Epub ahead of print]


Monteiro I, Vigano S, Faouzi M, Treilleux I, Michielin O, Ménétrier-Caux C, Caux C, Romero P, de Leval L.
CD73 expression and clinical significance in human metastatic melanoma.
Oncotarget. 2018 Jun 1;9(42):26659-26669. doi: 10.18632/oncotarget.25426. eCollection 2018 Jun 1.


Cardoso E, Mercier T, Wagner AD, Homicsko K, Michielin O, Ellefsen-Lavoie K, Cagnon L, Diezi M, Buclin T, Widmer N, Csajka C, Decosterd L.
Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.
J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Apr 15;1083:124-136. doi: 10.1016/j.jchromb.2018.02.008. Epub 2018 Feb 8.


Voruz S, Martins F, Cairoli A, Naveiras O, Homicsko K, Missiaglia E, de Leval L, Bisig B, Michielin O, Blum S.
Comment on "MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma".
Haematologica. 2018 Mar;103(3):e130. doi: 10.3324/haematol.2017.186932.


Wouters MW, Michielin O, Bastiaannet E, Beishon M, Catalano O, Del Marmol V, Delgado-Bolton R, Dendale R, Trill MD, Ferrari A, Forsea AM, Kreckel H, Lövey J, Luyten G, Massi D, Mohr P, Oberst S, Pereira P, Prata JPP, Rutkowski P, Saarto T, Sheth S, Spurrier-Bernard G, Vuoristo MS, Costa A, Naredi P.
ECCO essential requirements for quality cancer care: Melanoma.
Crit Rev Oncol Hematol. 2018 Feb;122:164-178. doi: 10.1016/j.critrevonc.2017.12.020. Epub 2018 Jan 2. Review.


Tétu P, Mangana J, Dummer R, Dutriaux C, Beneton N, Dalle S, Meyer N, Oriano B, Michielin O, Lebbe C.
Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma.
Eur J Cancer. 2018 Apr;93:147-149. doi: 10.1016/j.ejca.2018.01.062. Epub 2018 Feb 12.


Voruz S, Cairoli A, Naveiras O, de Leval L, Missiaglia E, Homicsko K, Michielin O, Blum S.
Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma.
Haematologica. 2018 Jan;103(1):e39-e41. doi: 10.3324/haematol.2017.179150. Epub 2017 Nov 2.


 

google analytics